References
1. Hill, L., Alousi, A., Kebriaei, P., Mehta, R., Rezvani, K., Shpall, E. New and emerging therapies for acute and chronic graft versus host disease. Therapeutic Advances in Hematology. 2018; 9:21-46.
2. Al-Homsi, A. S., et al. Bortezomib for the prevention and treatment of graft-versus-host-disease after allogenic hematopoietic stem cell transplantation. Experimental Hematology. 2016; 44: 771-777.
3. Kuroda, J., et al. Bortezomib for post-allogenic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience. International Journal of Hematology. 2010; 92: 669-672.
4. Kumar, S., Mohammadpour, H., Cao, X. Targeting Cytokines in GVHD Therapy. Journal of Immunology research and therapy. 2017. 2: 90-99.
5. Toubai, T., Sun, Y., Reddy, P. GVHD Pathophysiology: is acute different from chronic? Best practice and research: Clinical haematology. 2008. 21: 101-117.
6. Ram, R. and Storb, R. Pharmacologic Prophylaxis Regimens for Acute GVHD – Past, Present, and Future. 2013. 54: 1591-1601.
7. Vodanovic-Jankovic, S., Hari P., Jacobs, P., Komorowski, R., Drobyski, W. R. NF-κB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145 2006.
8. Sun, Kai, E.C, Danice, Anyer, Miriam R, et al. Differential Effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. 2005 106:3293-3299; doi: https://doi.org/10.1182/blood-2004-11-4526
9. Malard F, Labopin M, Yakoub-Agha I, et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood  2017; 130 (20): 2186–2195. doi: https://doi.org/10.1182/blood-2017-05-786137
10. Carpenter PA, MacMillan ML. Management of acute graft-versus-host disease in children. The Pediatric clinics of North America . 2010;57(1):273-295. doi: 10.1016/j.pcl.2009.11.007
11. Drobyski, W.R., Pasquini, M., Kovatovic, K. et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease.Biol Blood Marrow Transplant . 2011; 17: 1862–1868
12. Koreth, J., Stevenson, K.E., Kim, H.T. et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol . 2012; 30: 3202–320
13. Koreth, J., Stevenson, K.E., Kim, H.T. et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood . 2009; 114: 3956–3959
14. Pai, C. S., Hsiao, H., Sun, K. et al. Therapeutic benefit of bortezomib on acute GVHD is tissue specific and is associated with IL-6 levels. Biol Blood Marrow Transplant. 2014; 20: 1899-19020.
15. BS Sleight, KW Chan, TM Braun, A Serrano and AL Gilman. Infliximab for GVHD therapy in children Bone Marrow Transplantation (2007) 40, 473–480.